To date, venetoclax (ABT-199) has already been approved for the clinic, while BCL-xL and MCL-1 inhibitors are showing clinical efficacy but may be associated with undesired secondary effects such as thrombocytopenia or cardiac toxicity, respectively [14]. This evidence concerns the gene MCL1 and Thrombocytopenia.